Shionogi, a pharmaceutical research company, offered its latest information on the antibiotic agent cefiderocol and S-033188, a product that is being tested to treat influenza, at the recent IDWeek 2017, the annual meeting of the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA) and the Pediatric Infectious Diseases Society (PIDS), the company said.
Shionogi said in a release that cefidercol is an "investigational siderophore cephalosporin with a novel mechanism of cell entry in late stage development with activity against a broad range of gram-negative pathogens." Some of the pathogens are very resistant to agents including "colistin, and carbapenem-resistant strains of Pseudomonas aeruginosa, Acinetobacter baumannii and Enterobacteriaceae (CRE) and Stenotrophomonas maltophilia," the release said
S-033188 is a cap-dependent endonuclease inhibitor that, if researchers are successful, will only need to be taken once in order to treat influenza, the release said. The product has the "potential to deliver higher potency antiviral effects than existing marketed anti-influenza products," the release said